Table 1 Cyclophosphamide experiences of the clinicians

Professional experience of physicians

 1–3 years

10 (18%)

2 (6%)

0.139

 4–6 years

20 (36%)

6 (19%)

0.110

 7–10 years

16 (28%)

2 (6%)

0.014

 >10 years

8 (14%)

21 (68%)

< 0.001

Number of CYC performed by physicians

 1–19 times

31 (55%)

14 (45%)

0.362

 20–50 times

12 (21%)

7 (23%)

0.900

 >50 times

13 (23%)

10 (32%)

0.359

The most common disease for which CYC is used

 SLE

55 (98%)

28 (90%)

0.092

 AAV

42 (75%)

19 (61%)

0.180

In which disease is CYC therapy used for induction therapy?

 SLE

55 (98%)

28 (90%)

0.092

 AAV

42 (75%)

18 (58%)

0.102

 Takayasu arteritis

28 (50%)

2 (6%)

< 0.001

 Systemic PAN

30 (54%)

4 (13%)

< 0.001

 IgA vasculitis

4 (7%)

9 (29%)

0.006

 Juvenile scleroderma

12 (21%)

1 (3%)

0.022

 Juvenile dermatomyositis

15 (27%)

N/A

 IgG4 related disease

3 (5%)

1 (3%)

0.649

 SRNS

N/A

9 (29%)

 SDRS

N/A

5 (16%)

 SDFRNS

N/A

6 (19%)

SLE system involvement in which CYC is used

 Kidney (Class III and Class IV)

56 (100%)

31 (100%)

 Neurologic

52 (93%)

5 (16%)

0.000

 Hematologic

17 (30%)

1 (3%)

0.002

Treatments used in CYC-resistant SLE

 Corticosteroids

56 (100%)

31 (100%)

 RTX

13 (23%)

5 (16%)

0.434

 MMF

44 (79%)

19 (61%)

0.084

 CSA or tacrolimus

1 (2%)

4 (13%)

0.032

 IVIG

17 (30%)

4 (13%)

0.068

What agents do you use before CYC in SRNS?

 Pulse methylprednisolone/oral prednisolone

N/A

31 (100%)

 MMF

N/A

9 (29%)

 CSA or tacrolimus

N/A

17 (55%)

 Levamisole

N/A

5 (16%)